BIOSANTE PHARMACEUTICALS INC Form SC 13G/A August 24, 2009

OMB APPROVAL
OMB Number: 3235-0145
Expires: February 28, 2009
Estimated average burden hours per response. . . 11

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No. 1)

Biosante Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
09065V203
(CUSIP Number)
August 14, 2009
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[] Rule 13d-1(b)
[X] Rule 13d-1(c)

[] Rule 13d-1(d)

The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be 'filed' for the purpose of Section 18 of the Securities Exchange Act of 1934 ('Act') or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 09065V203

Person 1				
	1.	(a) Names of Reporting Persons. MOG Capital, LLC		
		(b) Tax ID		
		20-3254923		
	2.	Check the Appropriate Box if a Member of a Group (See Instructions)		
		(a) []		
		(b) []		
	3.	SEC Use Only		
	4.	Citizenship or Place of Organization New York, United States		
Number of		5. Sole Voting Power 0		
Shares Beneficially Owned by Each Reportin	ng	6. Shared Voting Power 3,250,000 Refer to Statement below		
Person With		7. Sole Dispositive Power 0		
		8. Shared Dispositive Power 3,250,000 Refer to Statement below		
	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 3,250,000		
	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)		

11. Percent of Class Represented by Amount in Row (9) 9.8357 %

12. Type of Reporting Person (See Instructions)

BD

Item 1.

(a) Name of Issuer
Biosante Pharmaceuticals, Inc.

(b) Address of Issuer's Principal Executive Offices
111 Barclay Blvd., Lincolnshire, IL 60069

Item 2.

- (a) Name of Person Filing MOG Capital, LLC
- (b) Address of Principal Business Office or, if none, Residence 2 Rector Street, 3rd Floor, New York, NY 10006
- (c) Citizenship New York, United States
- (d) Title of Class of Securities Common Stock
- (e) CUSIP Number 09065V203

Item If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)	[]	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78c)
(b)	[]	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
(c)	[]	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
(d)	[]	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
(e)	[An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);

- (f) [An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
- (g) [A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
- (h) [A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act [12 U.S.C. 1813);
- (i) [A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) [A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
- (k) [Group, in accordance with 240.13d-1(b)(1)(ii)(K).If filing as a non-U.S. institution in accordance with 240.13d-1(b)(ii)(J), please specify the type of institution:

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount beneficially owned: 3,250,000
- (b) Percent of class: 9.8357%
- (c) Number of shares as to which the person has:
 - (i) Sole power to vote or to direct the vote 0
 - (ii) Shared power to vote or to direct the vote 3,250,000 Refer to Statement below
 - (iii) Sole power to dispose or to direct the

disposition of 0

(iv) Shared power to dispose or to direct the

disposition of 3,250,000 Refer to Statement

below

Person 2

- (a) Names of Reporting Persons.
 MOG Capital, LLC
 - (b) Tax ID 20-3254923
- 2. Check the Appropriate Box if a Member of a Group (See Instructions)

	(a) [] (b) []	
3.	SEC Use Only	
4.	Citizenship or Place of Organization New York, United States	
Number of Shares	5. Sole Voting Power 0	
Beneficially Owned by Each Reporting	6. Shared Voting Power 3,250,000 Refer to Statement below	
Person With	7. Sole Dispositive Power 0	
	8. Shared Dispositive Power 3,250,000 Refer to Statement below	
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 3,250,000	
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)	
11.	Percent of Class Represented by Amount in Row (9) 9.8357% %	
12.	Type of Reporting Person (See Instructions)	
BD		

Item 1.

- (a) Name of Issuer Biosante Pharmaceuticals, Inc.
- (b) Address of Issuer's Principal Executive Offices111 Barclay Blvd., Lincolnshire, IL 60069

Item 2.

- (a) Name of Person Filing MOG Capital, LLC
- (b) Address of Principal Business Office or, if none, Residence 2 Rector Street, 3rd Floor, New York, NY 10006
- (c) Citizenship New York, United States
- (d) Title of Class of Securities Common Stock
- (e) CUSIP Number 09065V203

Item If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) [Broker or dealer registered under section 15 of the Act (15 U.S.C. 78c)
- (b) [Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c) [Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
- (d) [Investment company registered under section 8 of the Investment Company Act of 1940 | (15 U.S.C 80a-8).
- (e) [An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);]
- (f) [An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
- (g) [A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
- (h) [A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act [12 U.S.C. 1813);
- (i) [A church plan that is excluded from the definition of an investment company under section
 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) [A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);.]
- (k) [Group, in accordance with 240.13d-1(b)(1)(ii)(K).If filing as a non-U.S. institution in accordance with 240.13d-1(b)(ii)(J), please specify the type of institution:

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

	(a)	Amount beneficially owned: 3,250,000			
	(b)	Percent of class: 9	0.8357%%		
(c) Nur		Number of shares	umber of shares as to which the person has:		
		(i)	Sole power to vote or to direct the vote 0		
		(ii)	Shared power to vote or to direct the vote 3,250,000 Refer to Statement below		
		(iii)	Sole power to dispose or to direct the disposition of 0		
		(iv)	Shared power to dispose or to direct the disposition of 3,250,000 Refer to Statement below		
Person 3					
	1.	(a) Names of Repo			
		(b) Tax ID 26-1107229			
	2.	Check the Appropriate Box if a Member of a Group (See Instructions)			
		(a) []			
		(b) []			
	3.	SEC Use Only			
	4.	Citizenship or Plac	ce of Organization Delaware, USA		
Number o Shares	of		5. Sole Voting Power 0		
Beneficially Owned by Each Reporting			6. Shared Voting Power 3,250,000		
Person W	ıth				

$\overline{}$	C - 1 -	T		Power	$^{\circ}$
,	NOI P	1 1100	MC1T1VA	POWer	
	JUIC		OSILI V C		v

8. Shared Dispositive Power 3.	.250,000
--------------------------------	----------

- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 3,250,000
- 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
- 11. Percent of Class Represented by Amount in Row (9) 9.8357% %
- 12. Type of Reporting Person (See Instructions)

00

Item 1.

- (a) Name of Issuer Biosante Pharmaceuticals, Inc.
- (b) Address of Issuer's Principal Executive Offices
 - 111 Barclay Blvd., Lincolnshire, IL 60069

Item 2.

- (a) Name of Person Filing Alphabet Advisors, LLC
- (b) Address of Principal Business Office or, if none, Residence 2 Rector Street, 3rd Floor, New York, 10006
- (c) Citizenship Delaware, USA
- (d) Title of Class of Securities Common Stock
- (e) CUSIP Number 09065V203

Item If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78c) (a) [(b) [Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). 1 Investment company registered under section 8 of the Investment Company Act of 1940 (d) [(15 U.S.C 80a-8). (e) [An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); (f) [] (g) [A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (h) [(12 U.S.C. 1813); A church plan that is excluded from the definition of an investment company under section (i) [3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);. (j) [] Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance (k) [with 240.13d-1(b)(ii)(J), please specify the type of institution:

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount beneficially owned: 3,250,000(b) Percent of class: 9.8357%%
- (c) Number of shares as to which the person has:
 - (i) Sole power to vote or to direct the vote 0
 - (ii) Shared power to vote or to direct the vote 3,250,000
 - (iii) Sole power to dispose or to direct the disposition of 0
 - (iv) Shared power to dispose or to direct the disposition of 3,250,000

Person 4			
1.	(a) Names of Reporting Persons. Alphabet Management, LLC		
	(b) Tax ID		
	26-1107179		
2.	Check the Appropriate Box if a Member of a Group (See Instructions)		
	(a) []		
	(b) []		
3.	SEC Use Only		
4.	Citizenship or Place of Organization Delaware, USA		
Number of Shares	5. Sole Voting Power 0		
Beneficially Owned by Each Reporting	6. Shared Voting Power 3,250,000		
Person With	7. Sole Dispositive Power 0		
	8. Shared Dispositive Power 3,250,000		
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 3,250,000		
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)		
11.	Percent of Class Represented by Amount in Row (9) 9.8357% %		
12.	Type of Reporting Person (See Instructions)		

Item 1.

- (a) Name of Issuer Biosante Pharmaceuticals, Inc.
- (b) Address of Issuer's Principal Executive Offices
 - 111 Barclay Blvd., Lincolnshire, IL 60069

Item 2.

- (a) Name of Person Filing
 Alphabet Management, LLC
- (b) Address of Principal Business Office or, if none, Residence 2 Rector Street, 3rd Floor, New York, NY 10006
- (c) Citizenship Delaware, USA
- (d) Title of Class of Securities Common Stock
- (e) CUSIP Number 09065V203

Item If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) [Broker or dealer registered under section 15 of the Act (15 U.S.C. 78c)]
- (b) [Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c) [Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
- (d) [Investment company registered under section 8 of the Investment Company Act of 1940] (15 U.S.C 80a-8).
- (e) [An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
- (f) [An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
- (g) [A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
- (h) [A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act [(12 U.S.C. 1813);

(1) [3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);				
(j) [1	A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);.				
(k) [•				
Item 4.		Ownership.			
	e following in tified in Item		g the aggregate number and percentage of the class of securities of the		
	(a)	Amount beneficial	ly owned: 3,250,000		
	(b)	Percent of class: 9	.8357%%		
	(c)	Number of shares a	as to which the person has:		
		(i)	Sole power to vote or to direct the vote 0		
		(ii)	Shared power to vote or to direct the vote 3,250,000		
		(iii)	Sole power to dispose or to direct the disposition of 0		
		(iv)	Shared power to dispose or to direct the disposition of 3,250,000		
Person 5					
	1.	(a) Names of Repo Jason Adler	rting Persons.		
		(b) Tax ID			
	2.	Check the Appropr	riate Box if a Member of a Group (See Instructions)		
		(a) []			
		(b) []			
	3.	SEC Use Only			
	4.	Citizenship or Plac	e of Organization United States		

Number of Shares Beneficially Owned by Each Reporting Person With	5. Sole Voting Power 06. Shared Voting Power 3,250,0007. Sole Dispositive Power 0	
	8. Shared Dispositive Power 3,250,000	
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 3,250,000	
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)	
11.	Percent of Class Represented by Amount in Row (9) 9.8357% %	
12.	Type of Reporting Person (See Instructions)	
IN		

Item 1.

- (a) Name of Issuer Biosante Pharmaceuticals, Inc.
- (b) Address of Issuer's Principal Executive Offices111 Barclay Blvd., Lincolnshire, IL 60069

Item 2.

- (a) Name of Person Filing Jason Adler
- (b) Address of Principal Business Office or, if none, Residence 2 Rector Street, 3rd Floor, New York, NY 10006
- (c) Citizenship United States

- (d) Title of Class of Securities Common Stock
- (e) CUSIP Number 09065V203

Item If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) [Broker or dealer registered under section 15 of the Act (15 U.S.C. 78c)
- (b) [Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c) [Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
- (d) [Investment company registered under section 8 of the Investment Company Act of 1940] (15 U.S.C 80a-8).
- (e) [An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
- (f) [An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
- (g) [A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
- (h) [A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act [12 U.S.C. 1813);
- (i) [A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) $\begin{bmatrix} A \text{ non-U.S. institution in accordance with } 240.13\text{d-1(b)}(1)(ii)(J);. \end{bmatrix}$
- (k) [Group, in accordance with 240.13d-1(b)(1)(ii)(K).If filing as a non-U.S. institution in accordance with 240.13d-1(b)(ii)(J), please specify the type of institution:

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount beneficially owned: 3,250,000
- (b) Percent of class: 9.8357%%
- (c) Number of shares as to which the person has:
 - (i) Sole power to vote or to direct the vote 0

	(ii)	Shared power to vote or to direct the vote 3,250,000
	(iii)	Sole power to dispose or to direct the disposition of 0
	(iv)	Shared power to dispose or to direct the disposition of 3,250,000
Person 6		
1.	(a) Names of Andrew Ga	of Reporting Persons.
	(b) Tax ID	
2.		Appropriate Box if a Member of a Group (See Instructions)
	(a) [] (b) []	
3.	SEC Use O	nly
4.	Citizenship	or Place of Organization United States
Number of Shares		5. Sole Voting Power 0
Beneficially Owned by Each Reporting		6. Shared Voting Power 3,250,000
Person With		7. Sole Dispositive Power 0
		8. Shared Dispositive Power 3,250,000
9.	Aggregate A	Amount Beneficially Owned by Each Reporting Person 3,250,000
10.	Check if the	e Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

- 11. Percent of Class Represented by Amount in Row (9) 9.8357% %

 12. Type of Reporting Person (See Instructions)

 IN

 Item 1.

 (a) Name of Issuer
 Biosante Pharmaceuticals, Inc.

 (b) Address of Issuer's Principal Executive Offices
 111 Barclay Blvd., Lincolnshire, IL 60069

 Item 2.
 - (a) Name of Person Filing Andrew Garnock
 - (b) Address of Principal Business Office or, if none, Residence 2 Rector Street, 3rd Floor, New York, NY 10006
 - (c) Citizenship United States
 - (d) Title of Class of Securities Common Stock
 - (e) CUSIP Number 09065V203

Item If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a) [Broker or dealer registered under section 15 of the Act (15 U.S.C. 78c)
[Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
[Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
[Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

- (e) [An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
- (f) [An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
- (g) [A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
- (h) [A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) [A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) [A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);.]
- (k) [Group, in accordance with 240.13d-1(b)(1)(ii)(K).If filing as a non-U.S. institution in accordance with 240.13d-1(b)(ii)(J), please specify the type of institution:

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount beneficially owned: 3,250,000
- (b) Percent of class: 9.8357%%
- (c) Number of shares as to which the person has:
 - (i) Sole power to vote or to direct the vote 0
 - (ii) Shared power to vote or to direct the vote 3,250,000
 - (iii) Sole power to dispose or to direct the disposition of 0
 - (iv) Shared power to dispose or to direct the disposition of 3,250,000

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. [].

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

MOG Capital, LLC is a proprietary trading firm owned 100% by Alphabet Partners, L.P. Alphabet Partners, L.P. (the "Partnership") is a private investment partnership, the general partner of which is Alphabet Advisors, LLC and investment manager of which is Alphabet Management, LLC. Alphabet

Management, LLC is also the manager of MOG Capital, LLC. Alphabet Advisors, LLC is the sole general partner of the Partnership and has the power to vote and dispose of the Common Stock. Accordingly, it may be deemed the "beneficial owner" of such Common Stock. As the investment manager of the Partnership and manager of MOG Capital, LLC, Alphabet Management, LLC has the power to vote and and dispose of the Common Stock owned by MOG Capital, LLC and, accordingly, may be deemed the beneficial owner of the Common Stock. The Managing Members of Alphabet Management, LLC and Alphabet Advisors, LLC are Jason Adler and Andrew Garnock. Messrs. Adler and Garnock share investment management duties.

Item Identification and Classification of the Subsidiary Which Acquired the Security BeingReported on By the Parent Holding Company or Control Person.

N/A

Item 8. Identification and Classification of Members of the Group

N/A

Item 9. Notice of Dissolution of Group

N/A

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

August 20, 2009

Date

Signature

By: Jason Adler

Title: Managing Member of Alphabet Management, LLC and Alphabet Advisors, LLC

Name/Title

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

Advisor Consultant Network, Inc. Copyright © 2007-2008

SIGNATURE 18